Discussion stirs around Abeona Therapeutics Inc. (NASDAQ:ABEO) this week; here is what analysts are saying.

April 17, 2018 - By Richard Conner

Abeona Therapeutics Inc. (NASDAQ:ABEO) Logo

Abeona Therapeutics Inc. (NASDAQ:ABEO) Ratings Coverage

Among 5 analysts covering Abeona Therapeutics (NASDAQ:ABEO), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Abeona Therapeutics had 13 analyst reports since November 2, 2017 according to SRatingsIntel. H.C. Wainwright maintained Abeona Therapeutics Inc. (NASDAQ:ABEO) rating on Thursday, January 4. H.C. Wainwright has “Buy” rating and $30.0 target. The rating was maintained by Cantor Fitzgerald on Monday, January 29 with “Buy”. RBC Capital Markets maintained it with “Buy” rating and $26.0 target in Tuesday, January 23 report. Cantor Fitzgerald maintained Abeona Therapeutics Inc. (NASDAQ:ABEO) on Wednesday, February 7 with “Buy” rating. The stock has “Buy” rating by RBC Capital Markets on Thursday, November 2. H.C. Wainwright maintained the stock with “Buy” rating in Thursday, April 12 report. The stock has “Buy” rating by H.C. Wainwright on Thursday, February 8. The rating was maintained by H.C. Wainwright with “Buy” on Wednesday, November 22. The stock of Abeona Therapeutics Inc. (NASDAQ:ABEO) earned “Buy” rating by Jefferies on Tuesday, November 21. The rating was maintained by H.C. Wainwright on Monday, April 2 with “Buy”. Below is a list of Abeona Therapeutics Inc. (NASDAQ:ABEO) latest ratings and price target changes.

12/04/2018 Broker: H.C. Wainwright Rating: Buy New Target: $30.0000 Maintain
02/04/2018 Broker: H.C. Wainwright Rating: Buy New Target: $30.0000 Maintain
20/03/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $36.0 Maintain
08/02/2018 Broker: H.C. Wainwright Rating: Buy New Target: $30.0 Maintain
07/02/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $34.0 Maintain
01/02/2018 Broker: H.C. Wainwright Rating: Buy New Target: $30.0 Maintain
29/01/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $34.0 Maintain
23/01/2018 Broker: RBC Capital Markets Rating: Buy New Target: $26.0 Maintain
04/01/2018 Broker: H.C. Wainwright Rating: Buy New Target: $30.0 Maintain
22/11/2017 Broker: H.C. Wainwright Rating: Buy New Target: $30.0 Maintain

The stock decreased 4.23% or $0.85 during the last trading session, reaching $19.25. About 1.57 million shares traded or 32.58% up from the average. Abeona Therapeutics Inc. (NASDAQ:ABEO) has risen 188.66% since April 17, 2017 and is uptrending. It has outperformed by 177.11% the S&P500.

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy and plasma products for severe and life-threatening rare diseases. The company has market cap of $909.12 million. The companyÂ’s lead programs are ABO-101, an adeno-associated virus based gene therapies for Sanfilippo syndrome type B; and ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A. It currently has negative earnings. It is also developing EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); EB-201 for for epidermolysis bullosa (EB); ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; ABO-301, an AAV gene therapy for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9 gene editing approach to gene therapy program for rare blood diseases.

Abeona Therapeutics Inc. (NASDAQ:ABEO) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: